September 20, 2017

Dear SoonerCare Provider,

The purpose of this fax is to provide updates regarding coverage of antidepressant medications and fibric acid derivative medications, effective October 4, 2017.

The following changes will be made to the Antidepressant category:

1. Fluoxetine capsules will be preferred over fluoxetine tablets.
   a. Fluoxetine capsules will be available without a prior authorization. The tablet formulation will require prior authorization and reasoning why the tablet formulation is required in place of the capsule formulation.
2. Desvenlafaxine will be moved from Tier-3 to Tier-2. Current Tier-2 criteria will apply.
3. Trazodone 300mg tablets will be moved from Tier-1 to the Special Prior Authorization Tier.
   a. Authorization of the 300mg tablets will require a reason why the member cannot use (2) 150mg tablets or (3) 100mg tablet in place of the 300mg tablet.

Members currently taking fluoxetine tablets or trazodone 300mg tablets will not be “grandfathered.” Prior authorization request forms can be found online at www.okhca.org/forms (PHARM-04). Updated versions of the prior authorization criteria for the antidepressant medications can be downloaded from www.okhca.org/pa, by selecting “Central Nervous System/Behavioral Health.”

The following changes will be made to the Fibric Acid category:

1. Fibricor® (fenofibric acid) 35mg tablets will be moved from Tier-2 to Tier-1.
2. Trilipix® (choline fenofibrate delayed-release) 135mg capsules and Lofibra® (fenofibrate micronized) 200mg capsules will be moved from Tier-1 to Tier-2. Current Tier-2 criteria will apply.

Updated versions of the prior authorization criteria for the fibric acid medications can be downloaded from www.okhca.org/pa, by selecting “Cardiovascular.” Prior authorization request forms can be found online at www.okhca.org/forms (PHARM-04).

Thank you for the services you provide to Oklahomans insured by SoonerCare!